BJOG An International Journal of Obstetrics & Gynaecology · 1993 · 156 citations · 21 references
MedicineHematologyObstetricsHemostasisHigh-risk PregnancyMaternal-fetal MedicineCoagulation AbnormalitiesEclampsiaHypertensive DisordersPregnancyThrombin GenerationThrombosisGestational Age MeasurementPlasminogen ActivatorsPreeclampsia PathophysiologyPregnancy-related HypertensionProthrombin ActivationVon Willebrand Factor Antigen
OBJECTIVE: To establish the plasma evolution of prothrombin fragments 1+2 (F 1+2), thrombin-antithrombin III complexes (TAT), fibrin fragment D-Dimers (DD), von Willebrand factor antigen (vWf), Type 1 plasminogen activator inhibitor antigen (PAI) and blood platelet count during normal pregnancy and to compare these values with those obtained in hypertensive or pre-eclamptic pregnancies. DESIGN: Cross-sectional study. SUBJECTS: Forty-seven healthy pregnant women with gestational age ranging between 5 and 40 weeks, and fourteen women with gestational age ranging between 25 and 38 weeks presenting with either gestational hypertension (n = 4) or pre-eclampsia (n = 10). Numbers of nulliparous women in the control, hypertension and pre-eclampsia groups were 13/47 (28%), 1/4 (25%) and 9/10 (90%), respectively. RESULTS: All six markers increased with gestational age in normal pregnant women (P < 0.01). Using the upper limit of 95% prediction interval obtained from regression curves as normality threshold, TAT showed the best sensitivity (71% vs < 30% for F1+2, DD, vWf, PAI and platelet count). CONCLUSION: TAT appears to be an interesting marker for detecting haemostatic system alterations in pregnancies complicated by hypertension or pre-eclampsia. A large prospective study to determine its clinical usefulness for such complicated pregnancies is currently in progress.
21
Enhanced thrombin generation in normal and hypertensive pregnancy
Karin Boer, Jan W. ten Cate, Augueste Sturk et al. · American Journal of Obstetrics and Gynecology · 1989 · 233 citations
Medicine, Gynecology, Obstetrics +14